EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]
EyePoint Pharmaceuticals, Inc. (EYPT)
Last eyepoint pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points EyePoint Pharmaceuticals Inc ( NASDAQ:EYPT ) has completed enrollment for its phase 3 trials, Lugano and Lucia, for Dureview in wet AMD, recruiting over 900 patients in just 7 months. The company has aligned with the FDA on a non-inferiority trial design for DME, which is considered clinically rigorous and de-risked. EyePoint Pharmaceuticals Inc ( NASDAQ:EYPT ) ended September 2025 with over $200 million in cash and equivalents, and a $172 million follow-on offering in October, extending operational funding into Q4 2027. Dureview is positioned as the first to file and first to market among investigational sustained delivery programs for wet AMD and DME, potentially offering a first-mover advantage. The company has a strong manufacturing capability with a GMP-compliant facility in Northbridge, Massachusetts, ready to support commercial launch. Negative Poin
Show less
Read more
Impact Snapshot
Event Time:
EYPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EYPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EYPT alerts
High impacting EyePoint Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
EYPT
News
- Eyepoint Pharmaceuticals (NASDAQ:EYPT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.MarketBeat
- EyePoint Pharmaceuticals (EYPT): Valuation Update Following Positive Phase 3 DURAVYU Safety Review [Yahoo! Finance]Yahoo! Finance
- EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration [Yahoo! Finance]Yahoo! Finance
- EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular DegenerationGlobeNewswire
- EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
EYPT
Earnings
- 11/5/25 - Miss
EYPT
Sec Filings
- 12/5/25 - Form 4
- 12/4/25 - Form 144
- 12/1/25 - Form 4
- EYPT's page on the SEC website